Dilpacimab
- Generic Name
- Dilpacimab
- Drug Type
- Biotech
- CAS Number
- 1791420-09-1
- Unique Ingredient Identifier
- F27LAH6D5O
Overview
Dilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab).
Background
Dilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
No FDA products found for this drug
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath